Nine of the thirteen members on the Food and Drug Administration's Pharmacy Compounding Advisory Committee were just named by Health Secretary Robert F. Kennedy Jr.
The Health Secretary has spent a single week handing the Food and Drug Administration panel that decides whether American compounding pharmacies can make seven unproven injectable peptides to people who already sell them. Nine new members Robert F. Kennedy Jr. added to the Pharmacy Compounding Advisory Committee in late June bring the body to thirteen total. By Ars Technica's count, nearly all of the new arrivals personally promote peptide use or have financial ties to wellness clinics that do. STAT News, reporting the same day, adds that some of those members "could financially benefit from their own rulings" if the panel recommends adding the drugs to the FDA's bulk compounding list.
The panel will convene July 23–24 to vote on that list. It is a vote the FDA's own career scientists had not been preparing the way for. Briefing documents the agency posted ahead of the meeting reaffirm the 2023 determination that the peptides "lack evidence of safety and efficacy" sufficient to justify expanded access. The Washington Post, citing the same documents, called the agency staff recommendation a direct undercut of Kennedy's push. NPR and the Guardian have confirmed the panel reshuffle from the same angle: a deciding committee suddenly swollen with members who already profit from the question they will answer.
What the committee decides is narrower than the political fight suggests and more consequential. The Pharmacy Compounding Advisory Committee advises the FDA on which bulk drug substances compounding pharmacies may use to prepare medicines for individual patients. Under current rules, peptides are treated as essentially unregulated knock-offs of drugs whose safety and dosing the agency has never approved. Add a peptide to the list, and a compounding pharmacy can prepare it on prescription. Keep it off, and the pharmacy cannot compound it for human use. Researchers, importers, and gray-market telehealth clinics have been the access channel instead.
Even as the committee prepares its policy vote, the FDA has been telling compounders to stop marketing the same peptides for many of the conditions now on the agenda. On June 8, 2026, FDA's Office of Compliance issued Warning Letter 730095 to Maximus Health Inc. dba Maximus, citing peptide products marketed for wound healing and other indications directly adjacent to the July 23–24 agenda. The juxtaposition is the tension: enforcement against the marketing channel is alive, while a committee vote could soon legitimize a compounding channel for the same drug class. RAPS and the National Law Review trace the regulatory mechanic: a "yes" vote sends a peptide into bulk drug status under section 503A of the federal drug law, the lever compounders have lobbied for.
The seven peptides on the agenda, grouped by the conditions being argued:
On July 23, the committee takes up BPC-157, pitched for ulcerative colitis; KPV, pitched for wound healing and inflammation; TB-500, also for wound healing; and MOs-C, pitched for obesity and osteoporosis.
On July 24, the committee takes up emideltide, pitched for opioid withdrawal, chronic insomnia, and narcolepsy; semax, pitched for cerebral ischemia, migraine, and trigeminal neuralgia; and epitalon, pitched for insomnia.
A second PCAC meeting, scheduled before the end of February 2027, will take up five more peptides and complete the list of twelve the FDA began reconsidering in April under pressure from the Department of Health and Human Services. The April reconsideration, also reported by Ars Technica, established that the roster moves sit inside a months-long HHS pressure campaign, not a one-week reaction.
Kennedy has framed the campaign himself. In prior public statements, as quoted by Ars Technica, he has called himself "a big fan" of peptides and pledged to "end aggressive suppression" of peptides by the FDA. The new committee composition is consistent with that stated stance. The briefing documents from FDA's own career scientists are the institutional counterpoint.
What to watch from here is concrete and narrow. First, how the committee votes on each peptide. Its recommendations are not binding, but they shape what the FDA does next, and with nine of thirteen members appointed by Kennedy, the math tilts. Second, whether FDA leadership accepts or pushes back on a recommendation that runs against its own scientists' briefing documents. The agency's career staff have already said, on the record, what they think the evidence shows. The committee Kennedy has built is now the body that gets the next word. The FDA's meeting calendar and the committee roster page are public; the reading is open to anyone willing to count.